Compare Enveric Biosciences Inc (ENVB) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs SiTime Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while SiTime Corporation trades at $654.38 (market cap $19.99B). The key difference: SiTime Corporation is far larger — about 2988× Enveric Biosciences Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and SiTime Corporation for 18 Days on average.
| ENVB | SITM | |
|---|---|---|
Market Cap | $6.69M | $19.99B |
Volume | 41,141 | 339,821 |
Sector | Health | Technology |
52-Week High | $10.80 | $901.60 |
52-Week Low | $1.27 | $252.76 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | -$1.60M | $19.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SiTime Corp (SITM) trades at $665.16, down 6.46% today but maintains strong analyst support with 100% buy ratings and a $751.43 consensus price target. The stock shows bullish technical signals with support at $659 and resistance at $678, while recent quarterly earnings consistently beat expectations. Revenue growth accelerated to 126.5% year-over-year in Q2 2026, driven by AI infrastructure demand and the Renesas acquisition, though current valuation metrics remain elevated with P/S at 37.99.
SITM presents significant growth potential as a precision timing specialist benefiting from AI data center expansion, with projected revenue growth and margin expansion. However, risks include high valuation multiples, insider selling activity, and dependence on sustained AI infrastructure spending. The stock's current pullback may offer entry opportunity given strong fundamental momentum and unanimous Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
